BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise
Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium. Now, the company has announced the next step for the theranostic approach and its wish to accelerate clinical development of both uTREAT and uTRACE in parallel. Curasight aims at starting a phase I/IIa basket trial in several indications and in order to finance this updated develoment strategy, the company aims at raising DKK 51.2 million in a rights issue. BioStock contacted CEO Ulrich Krasilnikoff to learn more.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se